Comparison 1. Terlipressin versus other vasoactive drugs.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality: bias control	10	474	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.88, 1.06]
1.1 Low risk of bias	2	94	Risk Ratio (M‐H, Random, 95% CI)	0.92 [0.63, 1.36]
1.2 High risk of bias	8	380	Risk Ratio (M‐H, Random, 95% CI)	0.97 [0.88, 1.07]
2 Mortality: type of vasoactive drug	10	474	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.88, 1.06]
2.1 Noradrenaline	7	306	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.88, 1.08]
2.2 Midodrine/octreotide	1	48	Risk Ratio (M‐H, Random, 95% CI)	0.71 [0.40, 1.28]
2.3 Octreotide	1	40	Risk Ratio (M‐H, Random, 95% CI)	0.75 [0.32, 1.77]
2.4 Dopamine/furosemide	1	80	Risk Ratio (M‐H, Random, 95% CI)	0.97 [0.77, 1.22]
3 Mortality: type of hepatorenal syndrome	10	474	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.88, 1.06]
3.1 Type 1 hepatorenal syndrome	9	375	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.87, 1.06]
3.2 Type 2 hepatorenal syndrome	3	99	Risk Ratio (M‐H, Random, 95% CI)	0.95 [0.68, 1.33]
4 Mortality: publication status	10		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
4.1 Full paper	8	374	Risk Ratio (M‐H, Random, 95% CI)	0.97 [0.83, 1.14]
4.2 Abstract	2	100	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.86, 1.08]
5 Hepatorenal syndrome: type of vasoactive drug	9	394	Risk Ratio (M‐H, Random, 95% CI)	0.79 [0.63, 0.99]
5.1 Noradrenaline	7	306	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.76, 1.21]
5.2 Midodrine/octreotide	1	48	Risk Ratio (M‐H, Random, 95% CI)	0.47 [0.30, 0.72]
5.3 Octreotide	1	40	Risk Ratio (M‐H, Random, 95% CI)	0.56 [0.33, 0.96]
6 Hepatorenal syndrome: type hepatorenal syndrome	9	394	Risk Ratio (M‐H, Random, 95% CI)	0.79 [0.63, 0.98]
6.1 Type 1 hepatorenal syndrome	8	335	Risk Ratio (M‐H, Random, 95% CI)	0.79 [0.62, 1.01]
6.2 Type 2 hepatorenal syndrome	2	59	Risk Ratio (M‐H, Random, 95% CI)	0.86 [0.36, 2.10]
7 Hepatorenal syndrome: publication status	9	394	Risk Ratio (M‐H, Random, 95% CI)	0.79 [0.63, 0.98]
7.1 Full paper articles	7	294	Risk Ratio (M‐H, Random, 95% CI)	0.82 [0.63, 1.06]
7.2 Abstracts	2	100	Risk Ratio (M‐H, Random, 95% CI)	0.72 [0.44, 1.17]
8 Serious adverse events, type of vasoactive drug	10	474	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.88, 1.06]
8.1 Noradrenaline	7	306	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.88, 1.08]
8.2 Midodrine/octreotide	1	48	Risk Ratio (M‐H, Random, 95% CI)	0.72 [0.42, 1.23]
8.3 Octreotide	1	40	Risk Ratio (M‐H, Random, 95% CI)	0.75 [0.32, 1.77]
8.4 Dopamine/furosemide	1	80	Risk Ratio (M‐H, Random, 95% CI)	0.97 [0.77, 1.22]
9 Serious adverse events, type of event	10		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
9.1 Death	10	474	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.88, 1.06]
9.2 Major cardiovascular events	7	323	Risk Ratio (M‐H, Random, 95% CI)	0.88 [0.13, 5.98]
10 Non‐serious adverse events	6	301	Risk Ratio (M‐H, Random, 95% CI)	1.82 [1.00, 3.31]
11 Non‐serious adverse event: types	6		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
11.1 Diarrhoea or abdominal pain, or both	5	221	Risk Ratio (M‐H, Random, 95% CI)	3.50 [1.19, 10.27]
11.2 Peripheral cyanosis	2	92	Risk Ratio (M‐H, Random, 95% CI)	3.0 [0.32, 27.83]
11.3 Minor cardiovascular events	6	301	Risk Ratio (M‐H, Random, 95% CI)	0.84 [0.37, 1.93]